Different antibody discovery approaches exist, but one that has gained increasing interest in the field of toxinology and antivenom research is phage display technology. In this review we have discussed the various strategies employed for generation of monoclonal antibodies their advantages, limitations and potential therapeutic applications. Antibody discovery has become increasingly important in almost all areas of modern medicine.
A prominent number of phage display derived antibodies are already approved for therapy and significant numbers are currently in clinical trials. Phage display involves genetically manipulating bacteriophage so that peptides or antibodies can be expressed on their surface (Fig. Phage display technology has gained impetus in the field of medical and health sciences, as a large repertoire of diverse recombinant antibodies, targeting various antigens have been generated in a short span of time. MAbs are the fastest growing class of biopharmaceuticals, with more than 25 derivatives are in clinical use and 7 of these have been isolated through phage display technology. In the last 3 to 4 decades, tremendous success has been manifested in the field of cancer therapy, autoimmune diseases, cardiovascular and infectious diseases. Monoclonal antibodies (mAbs) and their derivatives have achieved remarkable success as medicine, targeting both diagnostic and therapeutic applications associated with communicable and non-communicable diseases.
0 kommentar(er)
